search
Back to results

A Sleep Intervention in Type 1 Diabetes

Primary Purpose

Short Sleep Phenotype, Type1diabetes

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Sleep Opt-In
Healthy Living
Sponsored by
University of Illinois at Chicago
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Short Sleep Phenotype focused on measuring type 1 diabetes, glycemic control, sleep, diabetes distress

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • type 1 diabetes for one year or more
  • self-reported habitual sleep duration less than 6.5 hours per night during work- or weekdays
  • own a smartphone.

Exclusion Criteria:

  • insomnia
  • sleep apnea
  • severe hypoglycemia within past 6 months
  • treated with an insulin pump with hybrid closed-loop features
  • rotating shift or night shift work
  • estimated glomerular filtration rate less than 45 ml/min
  • heart failure
  • cirrhosis
  • chronic obstructive pulmonary disease requiring oxygen
  • actively treated for cancer or psychiatric problem
  • history of stroke
  • pregnant or planning pregnancy
  • HbA1c 10% or higher.

Sites / Locations

  • University of Illinois at Chicago

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Sleep-Opt-In

Healthy Living

Arm Description

Sleep optimization intervention

Health education

Outcomes

Primary Outcome Measures

Sleep Duration
change in minutes of sleep (actigraphy-derived)
Sleep Regularity
Change in sleep regularity (variability)

Secondary Outcome Measures

HbA1c
HbA1c (A1C%)
Glucose Variability
Change in glucose variability (CV%) (continuous glucose monitor derived)
Diabetes Distress
Change in Diabetes Distress Scale score, 6-point, 17-item Likert scale. The 17 items are summed. The sum score is divided by 17 to provide a mean item score. Higher scores indicate greater distress. Score interpretation: < 2.0 = little distress 2.0-2.9 = moderate distress 3.0 or greater = hah distress

Full Information

First Posted
July 13, 2018
Last Updated
February 15, 2021
Sponsor
University of Illinois at Chicago
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Chicago
search

1. Study Identification

Unique Protocol Identification Number
NCT03617770
Brief Title
A Sleep Intervention in Type 1 Diabetes
Official Title
A Sleep Intervention to Improve Glycemic Control and Reduce Diabetes Distress in Working Adults With Type 1 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Completed
Study Start Date
January 9, 2019 (Actual)
Primary Completion Date
November 20, 2019 (Actual)
Study Completion Date
November 20, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Illinois at Chicago
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Chicago

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Insufficient sleep and sleep irregularity (variability in sleep duration) are increasingly recognized as important contributors to glucose control and diabetes distress in type 1 diabetes (T1D). Up to 40% of adults with T1D had a sleep duration less than 6-6.5 hours per night. Diabetes distress is reported (40% prevalence) in individuals with T1D and is associated with poor glucose control. Despite findings that sleep disturbances are common in T1D, the current understanding of the effects of strategies to improve sleep on diabetes distress, and glucose control is limited. The purpose of this pilot study is to evaluate the effects of a sleep intervention on sleep duration, diabetes distress and glucose control in individuals with T1D and habitual short sleep. A randomized controlled trial in 20 adults aged 18 to 65 years with T1D is proposed. Eligible participants will be randomly assigned to a sleep intervention group or a control group. Differences between the two groups on the outcomes of sleep duration, diabetes distress and glucose control will be evaluated. Findings from this proposed pilot study will serve as the foundation for a larger clinical trial to improve sleep, reduce diabetes distress, and improve glucose control.
Detailed Description
Insufficient sleep and sleep irregularity (variability in sleep duration) are increasingly recognized as important contributors to glycemic control and diabetes distress in type 1 diabetes (T1D). Up to 40% of adults with T1D had a sleep duration < 6-6.5 hours per night, either by self-report or objectively assessed actigraphy. Diabetes distress is reported (40% prevalence) in individuals with T1D and is associated with poor glycemic control. Despite findings that sleep disturbances are common in T1D, the current understanding of the effects of sleep optimization on sleep, diabetes distress, and glycemic control is limited. The purpose of this pilot and feasibility trial is to evaluate the effects of a T1D-specific sleep optimization intervention (Sleep-Opt-In) on the outcomes of sleep, diabetes distress and glycemic control in individuals with T1D and habitual short sleep. The specific aims are to determine if Sleep-Opt-In will: 1) be feasible and acceptable to the target population; 2) result in improved sleep duration and regularity; 3) result in improved glycemic control; and 4) lower diabetes distress. To achieve these aims, a randomized controlled trial in 20 adults aged 18 to 65 years with T1D is proposed. Participants will be screened for habitual sleep duration < 6.5 hours per night. Eligible subjects will be randomized to the T1D-Sleep-Opt-In group or attention control group. A one-week run-in period is planned, with baseline measures of sleep (duration and regularity), glycemia (A1C, fructosamine, glycemic variability), and diabetes distress (Diabetes Distress Scale). The T1D-Sleep-Opt-In will entail a novel technology-assisted behavioral sleep extension intervention developed to leverage rapidly increasing public interest in sleep tracking by consumers (+500% in 3 years). This technology employs four elements: a wearable sleep tracker, didactic content, an interactive smartphone application, and brief telephone counseling. The intervention will be T1D-specific by addressing T1D-related sleep issues such as nocturnal hypoglycemia. The attention control group will participate in a healthy living information program. At completion (Week 8) and post-program (Weeks 12 and 24), baseline measures will be repeated to determine differences between the two groups and sustainability of the intervention. Findings from this proposed pilot study will serve as the foundation for a larger clinical trial to improve sleep, reduce diabetes distress, and improve glycemic control.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Short Sleep Phenotype, Type1diabetes
Keywords
type 1 diabetes, glycemic control, sleep, diabetes distress

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Sleep optimization intervention will be compared to a healthy living attention control
Masking
None (Open Label)
Allocation
Randomized
Enrollment
14 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sleep-Opt-In
Arm Type
Experimental
Arm Description
Sleep optimization intervention
Arm Title
Healthy Living
Arm Type
Active Comparator
Arm Description
Health education
Intervention Type
Behavioral
Intervention Name(s)
Sleep Opt-In
Intervention Description
8-week intervention that includes a wearable sleep tracker, didactic content, smartphone application and counseling
Intervention Type
Behavioral
Intervention Name(s)
Healthy Living
Intervention Description
8-week intervention that includes weekly telephone counseling on healthy living.
Primary Outcome Measure Information:
Title
Sleep Duration
Description
change in minutes of sleep (actigraphy-derived)
Time Frame
Assessing change between two time points:Week 0 to week 8
Title
Sleep Regularity
Description
Change in sleep regularity (variability)
Time Frame
Assessing change between two time points: from week 0 to week 8
Secondary Outcome Measure Information:
Title
HbA1c
Description
HbA1c (A1C%)
Time Frame
Change between two time points, week 0 to week 8
Title
Glucose Variability
Description
Change in glucose variability (CV%) (continuous glucose monitor derived)
Time Frame
Assessing change between two time points: from week 0 to week 8
Title
Diabetes Distress
Description
Change in Diabetes Distress Scale score, 6-point, 17-item Likert scale. The 17 items are summed. The sum score is divided by 17 to provide a mean item score. Higher scores indicate greater distress. Score interpretation: < 2.0 = little distress 2.0-2.9 = moderate distress 3.0 or greater = hah distress
Time Frame
Assessing change between two time points: from week 0 to week 8

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: type 1 diabetes for one year or more self-reported habitual sleep duration less than 6.5 hours per night during work- or weekdays own a smartphone. Exclusion Criteria: insomnia sleep apnea severe hypoglycemia within past 6 months treated with an insulin pump with hybrid closed-loop features rotating shift or night shift work estimated glomerular filtration rate less than 45 ml/min heart failure cirrhosis chronic obstructive pulmonary disease requiring oxygen actively treated for cancer or psychiatric problem history of stroke pregnant or planning pregnancy HbA1c 10% or higher.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pamela Martyn-Nemeth, PhD
Organizational Affiliation
University of Illinois at Chicago
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Illinois at Chicago
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Sleep Intervention in Type 1 Diabetes

We'll reach out to this number within 24 hrs